Hunogidon 28

Hunogidon 28 is a combined oral contraceptive tablet that contains the synthetic hormones desogestrel and ethinylestradiol, formulated with lactose anhydrous as an inactive ingredient. It is marketed in the European Union as a prescription‑only medication for preventing pregnancy, and is taken by mouth in tablet form. Each tablet delivers a fixed dose of the two hormones that work together to inhibit ovulation and create additional barriers to fertilization.

Hunogidon 28 is indicated for women who require reliable hormonal contraception. It may be prescribed as a primary method of birth control for individuals seeking a reversible, non‑sterilizing option. - Prevents pregnancy when taken as directed. - Provides cycle control and reduces the risk of ovulation‑related disorders. - May be used in women with regular menstrual cycles who have no contraindications to estrogen‑containing contraceptives. - Can be part of a combined hormonal regimen that includes other estrogen or progestin products under medical supervision. - Offers a convenient once‑daily oral dosing schedule.

Like all hormonal contraceptives, Hunogidon 28 may cause unwanted effects, most of which are mild and transient in many users. Common: - Nausea or mild stomach upset. - Headache, including tension‑type pain. - Breast tenderness or slight enlargement. - Irregular spotting or breakthrough bleeding. Serious: - Deep vein thrombosis or pulmonary embolism. - Severe hypertension or hypertensive crisis. - Allergic reactions such as rash, swelling, or anaphylaxis.

Before prescribing Hunogidon 28, clinicians should evaluate individual risk factors and contraindications to ensure safe use in each patient carefully. - History of thromboembolic disorders, such as deep vein thrombosis or stroke. - Uncontrolled hypertension, cardiovascular disease, or smoking over 15 cigarettes per day. - Current or past breast cancer, estrogen‑dependent tumors, or liver disease. - Known or suspected pregnancy, as the product is not indicated for use during gestation. - Use of combined hormonal contraceptives with other estrogen‑containing therapies without medical supervision.

Hunogidon 28 can interact with several medicines, altering its effectiveness or increasing the risk of adverse events for the patient. Avoid: - Strong enzyme inducers such as rifampin, carbamazepine, or phenytoin, which may reduce contraceptive efficacy. - Antifungal agents like ketoconazole that increase hormone levels and risk of estrogen‑related side effects. - St. John’s wort, a herbal supplement known to lower plasma concentrations of oral contraceptives. Use with caution: - Anticoagulants (e.g., warfarin) where hormonal changes may affect clotting parameters. - Antihypertensive drugs, especially ACE inhibitors or beta‑blockers, requiring blood pressure monitoring. - Other hormonal therapies, including hormone replacement or menopausal regimens, to avoid excess estrogen exposure.